Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
125 hedge funds and large institutions have $812M invested in Trillium Therapeutics Inc. in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 36 reducing their positions, and 23 closing their positions.
97% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $6.34M
44% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 36
2.2% less ownership
Funds ownership: 75.56% → 73.36% (-2.2%)
5% less funds holding
Funds holding: 131 → 125 (-6)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
27% less capital invested
Capital invested by funds: $1.12B → $812M (-$307M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$35.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.3M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$7.17M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.15M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$22.5M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$17.1M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$9.83M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.81M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.31M |
TRIL Hedge Fund Activity: Q1 2021 in Review
125 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2021, worth a combined $812M — down 27% from $1.12B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TRIL and 18 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 52 added.
The largest buyer was Eventide Asset Management, adding an estimated $35.6M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $22.5M sold.
- 125 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2021, down from 131 in Q4 2020.
- Funds reported $812M of Trillium Therapeutics Inc. stock for Q1 2021, down 27% quarter-over-quarter.
- 18 funds opened new Trillium Therapeutics Inc. positions in Q1 2021 and 23 closed out, a net change of -5 holders.
- The largest Trillium Therapeutics Inc. buyer in Q1 2021 was Eventide Asset Management, an estimated $35.6M added.
- The largest Trillium Therapeutics Inc. seller in Q1 2021 was Polar Capital Holdings, an estimated $22.5M sold.
Based on aggregated 13F filings for Q1 2021.